Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Jia Li, Muhammad Wasif SaifYale Cancer Center, Yale School of Medicine, New Haven CT, USAAbstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia Li, Muhammad Wasif Saif
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4d99a45cd9d247f0b2e0be29ea4bccc8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4d99a45cd9d247f0b2e0be29ea4bccc8
record_format	dspace
spelling	oai:doaj.org-article:4d99a45cd9d247f0b2e0be29ea4bccc82021-12-02T01:52:30ZCurrent use and potential role of bevacizumab in the treatment of gastrointestinal cancers1177-54751177-5491https://doaj.org/article/4d99a45cd9d247f0b2e0be29ea4bccc82009-09-01T00:00:00Zhttp://www.dovepress.com/current-use-and-potential-role-of-bevacizumab-in-the-treatment-of-gast-a3516https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Jia Li, Muhammad Wasif SaifYale Cancer Center, Yale School of Medicine, New Haven CT, USAAbstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.Keywords: advanced colon cancer, angiogenesis, bevacizumab, chemotherapy, metastatic, targeted therapy, vascular endothelial growth factor, gastric cancer, pancreatic cancer, hepatocellular cancer Jia LiMuhammad Wasif SaifDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 429-441 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Jia Li Muhammad Wasif Saif Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
description	Jia Li, Muhammad Wasif SaifYale Cancer Center, Yale School of Medicine, New Haven CT, USAAbstract: Angiogenesis is essential for cancer growth and metastasis. Vascular endothelial growth factor (VEGF) is a key modulator of angiogenesis. In addition, overexpression of VEGF is correlated with advanced disease and poor prognosis. Bevacizumab, a recombinant humanized anti-VEGF monoclonal antibody, is the first anti-angiogenic agent approved by Food and Drug Administration for use in treatment of human solid cancers. Although bevacizumab has received most attention for first-line treatment of advanced colorectal and nonsmall-cell lung cancer, there is a rapidly growing body of evidence for its efficacy in treatment of a number of other solid tumors. We present the current status and potential use of bevacizumab therapy in gastrointestinal cancers.Keywords: advanced colon cancer, angiogenesis, bevacizumab, chemotherapy, metastatic, targeted therapy, vascular endothelial growth factor, gastric cancer, pancreatic cancer, hepatocellular cancer
format	article
author	Jia Li Muhammad Wasif Saif
author_facet	Jia Li Muhammad Wasif Saif
author_sort	Jia Li
title	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
title_short	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
title_full	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
title_fullStr	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
title_full_unstemmed	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
title_sort	current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/4d99a45cd9d247f0b2e0be29ea4bccc8
work_keys_str_mv	AT jiali currentuseandpotentialroleofbevacizumabinthetreatmentofgastrointestinalcancers AT muhammadwasifsaif currentuseandpotentialroleofbevacizumabinthetreatmentofgastrointestinalcancers
_version_	1718402834016239616

Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers

Ejemplares similares